Focused on respiratory and inflammatory diseases, the company develops and commercializes small‑molecule medicines and maintains royalty interests in partnered therapies. Its revenue base is largely tied to royalties from global sales of inhaled respiratory treatments developed with partners, alongs...
1 member of Congress has disclosed 1 trade in Theravance Biopharma, Inc. (TBPH), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-03-24 | George Whitesides | sell | $15K – $50K |